The synergistic effects of APR246 with conventional chemotherapeutic drugs observed on both wild-type and mutant P53 AML cells [72] confirmed that APR246 did not require the presence of a mutant P53 protein to exert its effects. The gene discussed is TP53; the disease is acute myeloid leukemia.